Uveitis Market Report 2032: Epidemiology data, Treatment market, Therapies, FDA Approvals and Companies by DelveInsight | Tarsier Pharma, Oculis Pharma, Roche, Eli Lilly, Santen Inc, Aerie Pharmaceuticals, Allergan, Merck, Pfizer, Teva Pharma, Bayer AG, Novartis, EyePoint Pharmaceuticals, Amorphex Therapeutics Holdings, Astellas Pharma Inc,

The Uveitis market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted Uveitis market size from 2019 to 2032, segmented by seven major markets. The Report also covers current Uveitis treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities and assesses the underlying potential of the Uveitis market.

Markets Jul 27, 2023 Add to Reading List

Uveitis Market Report 2032: Epidemiology data, Treatment market, Therapies, FDA Approvals and Companies by DelveInsight | Tarsier Pharma, Oculis Pharma, Roche, Eli Lilly, Santen Inc, Aerie Pharmaceuticals, Allergan, Merck, Pfizer, Teva Pharma, Bayer AG, Novartis, EyePoint Pharmaceuticals, Amorphex Therapeutics Holdings, Astellas Pharma Inc,

(New York, USA) DelveInsight's "Uveitis Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of Uveitis, historical and forecasted epidemiology as well as the Uveitis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.

Some facts of the Uveitis Market Report are:

The total uveitis market size of in the 7MM was approximately USD 1,496 million in 2022 and is projected to increase during the forecast period (2023–2032).
Leading Uveitis companies working in the market are Tarsier Pharma, Oculis Pharma, Roche, Eli Lilly and Company, Acelyrin, Affibody Medical, Eyevensys, Priovant Therapeutics, Santen Inc, Aerie Pharmaceuticals, Allergan, Bausch Health, Merck, Pfizer Inc, Fera Pharmaceuticals, Teva Pharmaceutical Industries, EyePoint Pharmaceuticals, Amorphex Therapeutics Holdings, Astellas Pharma Inc, Bayer AG, Novartis, and others.
The total number of diagnosed prevalent cases of uveitis in the United States was around 382,883 in 2022.
Emerging Uveitis therapies such as TRS01, OCS-02, and RG6179 can potentially create a positive shift in the uveitis market size.

Uveitis Overview

Uveitis is a sight-threatening inflammatory disease affecting the middle uveal layer of the eye. The inflammation usually happens when the immune system fights an infection affecting the uveal tract (composed of the iris, choroid, and ciliary body) and adjacent structures (including the sclera, cornea, vitreous humor, retina, and optic nerve head).

Uveitis is one of the leading causes of visual morbidity, with over one-third of patients with uveitis having a visual impairment and accounting for about 10–15% of blindness cases worldwide. Uveitis can affect people of all ages and can vary significantly by geographic location and age of the patient. Anterior uveitis is the most prevalent form, accounting for approximately 50% of uveitis cases, while posterior uveitis is the least common.

Uveitis Market

The Uveitis market outlook of the report helps to build a detailed comprehension of the historical, current, and forecasted Uveitis market trends by analyzing the impact of current Uveitis therapies on the market and unmet needs, and drivers, barriers, and demand for better technology.

This segment gives a thorough detail of the Uveitis market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Uveitis market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, the Uveitis market in 7MM is expected to witness a major change in the study period 2019-2032.

Uveitis Epidemiology

The Uveitis epidemiology section provides insights into the historical and current Uveitis patient pool and forecasted trends for seven individual major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the Uveitis market report also provides the diagnosed patient pool, trends, and assumptions.

Uveitis Drugs Uptake

This section focuses on the uptake rate of the potential Uveitis drugs recently launched in the Uveitis market or expected to be launched in 2019-2032. The analysis covers the Uveitis market uptake by drugs, patient uptake by therapies, and sales of each drug.

Uveitis Drugs Uptake helps in understanding the drugs with the most rapid uptake and the reasons behind the maximal use of new drugs and allows the comparison of the drugs based on Uveitis market share and size, which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Uveitis Pipeline Development Activities

The Uveitis report provides insights into different therapeutic candidates in Phase II, and Phase III stages. It also analyses Uveitis key players involved in developing targeted therapeutics.

Uveitis Therapeutics Assessment

Major key companies are working proactively in the Uveitis Therapeutics market to develop novel therapies which will drive the Uveitis treatment markets in the upcoming years are Tarsier Pharma, Oculis Pharma, Roche, Eli Lilly and Company, Acelyrin, Affibody Medical, Eyevensys, Priovant Therapeutics, Santen Inc, Aerie Pharmaceuticals, Allergan, Bausch Health, Merck, Pfizer Inc, Fera Pharmaceuticals, Teva Pharmaceutical Industries, EyePoint Pharmaceuticals, Amorphex Therapeutics Holdings, Astellas Pharma Inc, Bayer AG, Novartis, and others.

Uveitis Report Key Insights

Uveitis Patient Population
Uveitis Market Size and Trends
Key Cross Competition in the Uveitis Market
Uveitis Market Dynamics (Key Drivers and Barriers)
Uveitis Market Opportunities
Uveitis Therapeutic Approaches
Uveitis Pipeline Analysis
Uveitis Current Treatment Practices/Algorithm
Impact of Emerging Therapies on the Uveitis Market

Table of Contents

Key Insights
Executive Summary
Uveitis Competitive Intelligence Analysis
Uveitis Market Overview at a Glance
Uveitis Disease Background and Overview
Uveitis Patient Journey
Uveitis Epidemiology and Patient Population
Uveitis Treatment Algorithm, Current Treatment, and Medical Practices
Uveitis Unmet Needs
Key Endpoints of Uveitis Treatment
Uveitis Marketed Products
Uveitis Emerging Therapies
Uveitis Seven Major Market Analysis
Attribute Analysis
Uveitis Market Outlook (7 major markets)
Uveitis Access and Reimbursement Overview
KOL Views on the Uveitis Market
Uveitis Market Drivers
Uveitis Market Barriers
Appendix
DelveInsight Capabilities
Disclaimer

About DelveInsight

DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.

Trending Report: